Disc Medicine, Inc. (NASDAQ:IRON) Given Average Recommendation of “Moderate Buy” by Analysts

Disc Medicine, Inc. (NASDAQ:IRON) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $104.80.

Several research analysts have commented on the company. TD Cowen reaffirmed a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th. Truist Financial lowered their target price on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Finally, Stifel Nicolaus dropped their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th.

Insider Buying and Selling

In related news, COO Jonathan Yen-Wen Yu sold 3,231 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $203,100.66. Following the completion of the sale, the chief operating officer owned 54,324 shares in the company, valued at $3,414,806.64. This trade represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Rahul Khara sold 2,853 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $179,339.58. Following the transaction, the insider owned 52,173 shares in the company, valued at $3,279,594.78. The trade was a 5.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 292,492 shares of company stock worth $25,423,925. 3.64% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine in the fourth quarter worth $33,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Disc Medicine in the 3rd quarter valued at about $38,000. CWM LLC lifted its stake in shares of Disc Medicine by 213.5% in the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares during the period. KBC Group NV acquired a new stake in shares of Disc Medicine in the fourth quarter valued at about $80,000. Finally, Avanza Fonder AB boosted its holdings in Disc Medicine by 54.0% during the third quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after buying an additional 585 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Price Performance

Shares of IRON opened at $61.10 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 23.45. Disc Medicine has a 1-year low of $30.82 and a 1-year high of $99.50. The stock has a market cap of $2.31 billion, a PE ratio of -10.20 and a beta of 0.87. The firm has a fifty day moving average price of $73.48 and a 200 day moving average price of $75.59.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to analysts’ expectations of $0.15 million. As a group, sell-side analysts anticipate that Disc Medicine will post -4.07 EPS for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.